Compare · PFE vs TVRD
PFE vs TVRD
Side-by-side comparison of Pfizer Inc. (PFE) and Tvardi Therapeutics Inc. (TVRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PFE and TVRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE carries a market cap of $304.95B.
- Over the past year, PFE is up 17.1% and TVRD is down 85.4% - PFE leads by 102.5 points.
- PFE has been more active in the news (10 items in the past 4 weeks vs 3 for TVRD).
- PFE has more recent analyst coverage (25 ratings vs 11 for TVRD).
- Company
- Pfizer Inc.
- Tvardi Therapeutics Inc.
- Price
- $26.98+1.20%
- $3.11+5.42%
- Market cap
- $304.95B
- -
- 1M return
- -1.21%
- -5.76%
- 1Y return
- +17.13%
- -85.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 11
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
Latest TVRD
- SEC Form DEFA14A filed by Tvardi Therapeutics Inc.
- SEC Form DEF 14A filed by Tvardi Therapeutics Inc.
- Tvardi Therapeutics downgraded by Barclays with a new price target
- SEC Form S-8 filed by Tvardi Therapeutics Inc.
- SEC Form POS EX filed by Tvardi Therapeutics Inc.
- SEC Form 424B3 filed by Tvardi Therapeutics Inc.
- SEC Form 10-K filed by Tvardi Therapeutics Inc.
- Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
- SEC Form 424B3 filed by Tvardi Therapeutics Inc.